Defining genomic, transcriptomic, proteomic, epigenetic, and phenotypic biomarkers with prognostic capability in male breast cancer: a systematic review.

Subarnarekha Chatterji, Emma Krzoska, Christopher W Thoroughgood, John Saganty, Peng Liu, Beatrix Elsberger, Rasha Abu-Eid, Valerie Speirs

Journal: The Lancet. Oncology 2023;24(2):e74-e85

PMID: 36725152

Full Text on Elsevier Science View on PubMed

Abstract

Although similar phenotypically, there is evidence that male and female breast cancer differ in their molecular landscapes. In this systematic review, we consolidated all existing prognostic biomarker data in male breast cancer spanning genetics, transcriptomics, proteomics, and epigenetics, and phenotypic features of prognostic value from articles published over a 29-year period (March 16, 1992, to May 1, 2021). We identified knowledge gaps in the existing literature, discussed limitations of the included studies, and outlined potential approaches for translational biomarker discovery and validation in male breast cancer. We also recognised STC2, DDX3, and DACH1 as underexploited markers of male-specific prognostic value in breast cancer. Finally, beyond describing the cumulative knowledge on the extensively researched markers oestrogen receptor-α, progesterone receptor, HER2, androgen receptor, and BRCA2, we highlighted ATM, CCND1, FGFR2, GATA3, HIF1-α, MDM2, TP53, and c-Myc as well studied predictors of poor survival that also aligned with several hallmarks of cancer.

Address: School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, UK; Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK.; School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, UK.; NHS Grampian, Aberdeen Royal Infirmary, Breast Unit, Aberdeen, UK.; School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, UK; Institute of Dentistry, University of Aberdeen, Aberdeen, UK.; School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, UK; Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK. Electronic address: [email protected].

DOI: 10.1016/S1470-2045(22)00633-7

Link outs

Free resources

Medical:

https://medlineplus.gov/malebreastcancer.html

Miscellaneous:

https://assays.cancer.gov/CPTAC-3279

Research Materials:

https://antibodies.cancer.gov/detail/CPTC-ATM-4

Subscription / membership required

Full Text Sources:

MeSH Terms: Male, Humans, Female, Prognosis, Breast Neoplasms, Male, Breast Neoplasms, Transcriptome, Proteomics, Biomarkers, Tumor, Genomics, Epigenesis, Genetic